Placebo for atorvastatin

DRUG4 trials

Sponsors

Pfizer, Organon and Co, VA Office of Research and Development

Conditions

Heart Failure With Preserved Ejection FractionHypercholesterolemiaHyperlipidemiaInflammation

Phase 1

Novel Approaches for Improving Vascular Function in Veterans With HFpEF

RecruitingNCT06312748

VA Office of Research and DevelopmentHeart Failure With Preserved Ejection Fraction, Inflammation

Start: 2021-05-19End: 2030-09-30Target: 90Updated: 2025-06-19

Phase 3

Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects Who Are Intolerant to Statins

CompletedNCT02135029

PfizerHyperlipidemia

Start: 2014-06-30End: 2015-11-30Updated: 2017-12-14

Ezetimibe (EZ)/Atorvastatin (Ator) (MK-0653C) vs. Ator in Chinese Hypercholesterolemic Participants (MK-0653C-439)

CompletedNCT03768427

Organon and CoHypercholesterolemia

Start: 2019-05-27End: 2021-04-01Updated: 2024-05-16

Efficacy and Safety Study of Ezetimibe (SCH 58235, MK-0653) in Addition to Atorvastatin in Participants With Coronary Heart Disease or Multiple Cardiovascular Risk Factors (P00693/MK-0653-030)

CompletedNCT03867318

Organon and CoHypercholesterolemia

Start: 2000-04-24End: 2001-11-16Updated: 2024-05-10

Related Papers

LDL-C Goal Attainment with Fixed-Dose Ezetimibe and Atorvastatin Versus High-Dose Atorvastatin in Chinese Patients: Subgroup Analysis of a Randomized Trial.

2026-01-19

Efficacy and Tolerability of Ezetimibe/Atorvastatin Fixed-dose Combination Versus Atorvastatin Monotherapy in Hypercholesterolemia: A Phase III, Randomized, Active-controlled Study in Chinese Patients.

2022-09-299 citations

Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab

New England Journal of Medicine2017-03-17355 citations